CURE CANCER, TRANSFORM LIVES

OUR SCIENCE

Redirecting the body’s natural anti-viral immune response towards cancer

Learn More

PATIENTS

T Cell Therapy Treatment:
How does it work?

Learn More

About Us

Tessa Therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapies. Our goal is to bring hope to cancer patients with no viable treatment options. Today, we are a leader in Virus-Specific T cell therapy and are conducting the world’s first FDA Phase III T cell therapy trial in a solid tumor indication.

Our Science

The immuno suppressive tumor microenvironment presents significant obstacles to the treatment of solid tumors with immunotherapy. Our Virus-Specific T cell (VST) technology overcomes these barriers and has shown promising clinical success.

Our Pipeline

We have a broad clinical pipeline targeting multiple cancer indications. Our lead product is currently in a multi-centre international Phase III trial and our Phase I trial targeting cervical and oropharyngeal cancer has demonstrated early clinical significance with minimal toxicities.

Patients First

We are committed to working towards our vision of a world without untreatable cancers. We are constantly advancing our deep understanding of the body’s immune system to design next-generation VST therapies which demonstrate persistence, durability, and tumor penetration with minimal side effects for patients. Visit our patients page to know more about our therapies, ongoing clinical trials and potential treatment process.

Tessa on Twitter

5 days ago
We celebrated @parkerici's second birthday with our friends at the Parker Institute at #AACR18. Cheers to many more birthdays! #PICITurnsTwo https://t.co/P2wo5i7Z8h
6 days ago
We recently sat down with @EricNgSCMP from @SCMP_News to discuss how our Virus-Specific T cell technology redirects the patient’s immune system against #cancer, and holds the promise for cancer patients in Asia and beyond. Read the full article here: https://t.co/fvtglQ4Dby